DERMALIX Efficacy on Diabetic Foot Ulcers
- Conditions
- Diabetic FootDiabetic Foot Ulcer
- Registration Number
- NCT03136822
- Lead Sponsor
- Dermis Pharma
- Brief Summary
(DERMALIX) (Patent number: PCT/TR2014/000251) is a bioactive wound dressing that was developed by Ege University School of Pharmacy Department of Pharmaceutical Technology. This dressing has been categorised as Class III medical device. This clinical study will be conducted in patients with diabetic foot ulcers.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 48
- Type 1 or 2 Patients diagnosed with diabetic foot ulcers
- Class I and II according to Wagner classification
- No infections confirmed with culture test
- No osteomyelitis and gangrene in the foot
- HbA1c values ≤ % 7.5
- Not active smoker
- No planned treatment of hyperbaric oxygen
- Patients who give consent for the study
- Patients with diabetic foot ulcer of class 3,4 and 5 according to Wagner classification
- Patients who are pregnant or breast-feeding or female who are in reproductive age applying no preservative method
- Patients who have mental conditions that lead to difficulties in comprehension
- Patients who may have compliance issues
- Patients who have been included to another interventional study with drug or medical device
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Recovery of the wound 100% 1 month The wound will be completely recovered
- Secondary Outcome Measures
Name Time Method Recovery of the wound 80% 1 month The wound will be recovered by 80%
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (1)
Ege University School of Medicine
🇹🇷Izmir, Turkey
Ege University School of Medicine🇹🇷Izmir, Turkey